![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 1999, p. 954-956, Vol. 43, No. 4
Laboratoire de Bactériologie,
Received 5 October 1998/Returned for modification 25 November
1998/Accepted 25 January 1999
Five clinical isolates of Mycoplasma hominis from three
different patients were examined for resistance to fluoroquinolones; some of these isolates were probably identical. All five isolates harbored amino acid substitutions in the quinolone
resistance-determining regions of both DNA gyrase (GyrA) and
topoisomerase IV (ParC or ParE). Furthermore, the novobiocin MIC for
three isolates showed a significant increase. This is the first
characterization of fluoroquinolone-resistant clinical mycoplasma
isolates from humans.
Fluoroquinolones are broad-spectrum
antibacterial agents that inhibit DNA gyrase and topoisomerase IV
activities (9, 11). Both enzymes are composed of two A and
two B subunits, encoded by the gyrA and gyrB
genes for DNA gyrase and parC and parE genes for
topoisomerase IV, respectively. We reported previously (1, 3) that three of these genes, gyrA, parC,
and parE, were associated with fluoroquinolone resistance in
Mycoplasma hominis. However, these studies focused only on
mutants selected in vitro. We have now characterized five clinical
isolates of M. hominis which exhibited high-level resistance
to various fluoroquinolones.
The first isolate, MHa, was isolated from the genitourinary tract of a
35-year-old AIDS patient treated successively with ofloxacin,
ciprofloxacin, and sparfloxacin for infections associated with a
chronic obstructive airway disease. The second and third isolates (MHb1
and MHb2) were isolated on two distinct occasions (6 months apart) from
lung aspirates from the same patient, a 46-year-old man with a chronic
obstructive pulmonary disease who was treated at least twice with
ciprofloxacin for lung infection. The fourth and fifth isolates, MHc1
and MHc2, respectively, were isolated, at the same time, from a
bronchoalveolar lavage specimen and laparotomy pus of a 25-year-old
immunocompromised woman presenting for respiratory distress syndrome.
She received three sequential treatments, 1 month each, with
ciprofloxacin for occasional fevers complicating a bone marrow transplantation.
Growth conditions and antibiotic susceptibility testing of the M. hominis strains have been previously described (1).
Chromosomal DNA of each of the five strains was used as a template in a
PCR to amplify the quinolone resistance-determining regions (QRDRs) of
the gyrA, gyrB, parC, and
parE genes as previously described (1, 3). The 5'
ends of the gyrB and parE genes were amplified with primers GBF (5'-CTTGCTATGAGAAATAGTGGA-3') and GBR
(5'-ACGGTTATTTTCAAACCTTTG-3') for gyrB
(12) and PEF (5'-CATCACTTAATTTGGGAAAGT-3') and
PER (5'-ATTCAATAGTAAGATTTGGCA-3') for parE
(2).
Table 1 summarizes the analyses of the
five clinical isolates of M. hominis in comparison to the
M. hominis reference strain, PG21. All five isolates had a
similar high level of quinolone resistance (8- to 16-fold-increased
MICs of ofloxacin and ciprofloxacin and a 50- to 100-fold-increased MIC
of sparfloxacin) and were found to carry mutations in both GyrA and
ParC or ParE subunits.
In GyrA, isolate MHa harbored a Glu87-to-Lys change (Escherichia
coli numbering), whereas isolates MHb1, MHb2, MHc1, and MHc2 had
Ser83-to-Leu substitutions. In addition, nucleotide sequence comparisons revealed that the five clinical isolates harbored gyrA silent mutations, compared with the reference strain,
PG21, at positions corresponding to residues 66, 80, 101, 106, 128, 132, and 150. In M. hominis, the Ser83-to-Leu change in GyrA
was also found in fluoroquinolone-resistant mutants selected in vitro. In contrast, the Glu87-to-Lys substitution selected in the clinical isolate MHa was found in none of the in vitro-selected mutants (1,
3).
In ParC, two amino acid alterations were found at positions 81 and 84 (E. coli numbering). The Glu84-to-Gly substitution was found
in MHa, whereas the Ser81-to-Pro change occurred in strains MHb1 and
MHb2. Silent mutations were also found at positions 84 and 85. In
laboratory mutants of M. hominis resistant to
fluoroquinolones, residue 84 was found to be the site of the most
prevalent substitution (3). The ParC Ser-to-Pro change found
in isolates MHb1 and MHb2 at position 81, a position much less
frequently altered than positions 80 and 84, has also been described to
occur in clinical isolates of Neisseria gonorrhoeae
(7).
As with the in vitro mutants of M. hominis (1,
3), none of the five clinical isolates was found to carry an
alteration in the GyrB QRDR, although silent mutations were identified
at positions 427, 435, 457, and 460. This clearly confirms the
prevalence of mutations in gyrA over those in
gyrB. However, it should be noticed that the amino acid
residue at position 426 in the GyrB subunit of the reference strain,
M. hominis PG21, is already an asparagine (12),
that amino acid always substituting for the aspartic acid at position
426 in the GyrB QRDR of quinolone-resistant bacteria previously described.
Determining the status of the ParE QRDRs revealed that isolates MHc1
and MHc2 harbored a Asp420-to-Asn substitution at the position
corresponding to residue 420 or 426 of the E. coli ParE or
GyrB, respectively. This ParE substitution was previously described to
occur in M. hominis mutants obtained in vitro (3)
and was shown to be critical for quinolone resistance (10, 14, 16, 19-21). The other ParE sites associated with quinolone
resistance (Table 2) in
Staphylococcus aureus (8, 20), E. coli
(4), and Streptococcus pneumoniae (17)
have not been found to be substituted in quinolone-resistant mutants of
M. hominis selected in vitro or in vivo. Also in three
isolates, silent mutations were detected in the codons encoding
residues 423, 428, 434, 445, and 473 of the ParE QRDR. Silent mutations
found in each of the topoisomerase II genes could be related to a
strain-to-strain polymorphism in the nucleotide sequences of these
genes.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mutations in the gyrA, parC,
and parE Genes Associated with Fluoroquinolone Resistance in
Clinical Isolates of Mycoplasma hominis
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
TABLE 1.
Amino acid changes in GyrA, ParC, and ParE in
quinolone-resistant clinical isolates of M. hominis
TABLE 2.
Amino acid changes in ParE (GrlB) QRDR associated with
quinolone resistance
Concerning the novobiocin susceptibility of the five fluoroquinolone-resistant mutants (Table 1), novobiocin MICs for three isolates, MHa, MHc1, and MHc2, showed a fourfold increase. For these strains, the 5' region of gyrB, including the novobiocin resistance loci described for other species (5, 13), and the homologous 5' region of parE were amplified and sequenced without revelation of any base change compared with the reference strain PG21. A possible active efflux system affecting the novobiocin MIC could be implicated.
Interestingly, isolates MHb1 and MHb2, isolated 6 months apart from the same patient, exhibited identical profiles of resistance to fluoroquinolones, novobiocin, and josamycin, a 16-member macrolide (Table 1); the only difference was in their susceptibilities to tetracyclines (doxycycline MIC for MHb2, 8 µg/ml). Strain MHa also showed decreased susceptibility to tetracyclines (Table 1). In the face of the associated tetracycline resistance of these M. hominis isolates, two hypotheses can be considered, one implicating the acquisition of the tetM gene (6) and the other involving an active efflux system (15). Isolates MHc1 and MHc2, isolated at the same time from two different sites in the same patient, have identical antibiotic susceptibility profiles and show the same mutations in QRDRs of their topoisomerase II genes (Table 1). It is tempting to speculate that the paired isolates (MHb1 and MHb2, MHc1 and MHc2) from one patient are closely related or even identical.
In conclusion, the presence of alterations of both the GyrA subunit of DNA gyrase and the ParC or ParE subunit of topoisomerase IV in clinical isolates of M. hominis is in good agreement with our previous studies showing that, in M. hominis mutants selected in vitro, high-level resistance to fluoroquinolones was associated with modifications in both enzyme targets. In a recent study of 20 clinical isolates of E. coli resistant to fluoroquinolones, the failure to detect mutations in the ParE QRDR led the authors to conclude that this region was not linked with the acquisition of quinolone resistance in E. coli clinical isolates (18). In contrast, the finding of a ParE alteration in M. hominis mutants selected in vitro (1, 3) and in vivo (this study), in addition to recent studies describing parE mutants in clinical isolates of S. aureus (19, 20) and S. pneumoniae (17), reinforces the implication of the topoisomerase IV ParE subunit in resistance to fluoroquinolones.
| |
ACKNOWLEDGMENTS |
|---|
We thank V. Napoli (Laboratoire d'Eylau, Paris, France) for the gift of strains MHb1 and MHb2 and L. Collet (Laboratoire de Bactériologie, Institut Paoli-Calmettes, Marseille, France) for the gift of strains MHc1 and MHc2.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. Phone: (33) 5.57.57.16.25. Fax: (33) 5.56.79.56.11. E-mail: cecile.bebear{at}u-bordeaux2.fr.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Bébéar, C. M., J. M. Bové, C. Bébéar, and J. Renaudin. 1997. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob. Agents Chemother. 41:269-273[Abstract]. |
| 2. |
Bébéar, C. M.,
A. Charron,
J. M. Bové,
C. Bébéar, and J. Renaudin.
1998.
Cloning and nucleotide sequence of the topoisomerase IV parC and parE genes of Mycoplasma hominis.
Antimicrob. Agents Chemother.
42:2024-2031 |
| 3. |
Bébéar, C. M.,
H. Renaudin,
A. Charron,
J. M. Bové,
C. Bébéar, and J. Renaudin.
1998.
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
Antimicrob. Agents Chemother.
42:2304-2311 |
| 4. | Breines, D. M., S. Ouabdesselam, E. Y. Ng, J. Tankovic, S. Shah, C. J. Soussy, and D. C. Hooper. 1997. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41:175-179[Abstract]. |
| 5. | Contreras, A., and A. Maxwell. 1992. gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase. Mol. Microbiol. 6:1617-1624[Medline]. |
| 6. |
Cummings, M., and W. McCormack.
1990.
Increase in resistance of Mycoplasma hominis to tetracyclines.
Antimicrob. Agents Chemother.
34:2297-2299 |
| 7. | Deguchi, D., M. Yasuda, N. Nakano, E. Kanematsu, S. Oseki, Y. Nishino, T. Esaki, S.-I. Maeda, I. Saito, and Y. Kawada. 1997. Rapid screening of point mutations of the Neisseria gonorrhoeae parC gene associated with resistance to quinolones. J. Clin. Microbiol. 35:948-950[Abstract]. |
| 8. |
Fournier, B., and D. C. Hooper.
1998.
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Antimicrob. Agents Chemother.
42:121-128 |
| 9. |
Gellert, M.,
K. Mizuuchi,
M. H. O'Dea, and H. A. Nash.
1976.
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Proc. Natl. Acad. Sci. USA
73:3872-3876 |
| 10. |
Ito, H.,
H. Yoshida,
M. Bogaki-Shonai,
T. Niga,
H. Hattori, and S. Nakamura.
1994.
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
Antimicrob. Agents Chemother.
38:2014-2023 |
| 11. |
Khodursky, A. B.,
E. L. Zechiedrich, and N. R. Cozzarelli.
1995.
Topoisomerase IV is a target of quinolones in Escherichia coli.
Proc. Natl. Acad. Sci.
92:11801-11805 |
| 12. |
Ladefoged, S. A., and G. Christiansen.
1994.
Sequencing analysis reveals a unique gene organization in the gyrB region of Mycoplasma hominis.
J. Bacteriol.
176:5835-5842 |
| 13. |
Muñoz, R.,
M. Bustamante, and A. de la Campa.
1995.
Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance.
J. Bacteriol.
177:4166-4170 |
| 14. | Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326[Abstract]. |
| 15. |
Paulsen, I. T.,
M. H. Brown, and R. A. Skurray.
1996.
Proton-dependent multidrug efflux system.
Microbiol. Rev.
60:575-608 |
| 16. | Périchon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167[Abstract]. |
| 17. | Pestova, E. V., R. Beyer, C. A. Noskin, and L. R. Peterson. 1998. Characterization of mutations in DNA gyrase and topoisomerase IV from clinical isolates of Streptococcus pneumoniae with variable resistance to fluoroquinolones and antimicrobial agents, abstr. V133, p 535. In Program and abstracts of the 98th General Meeting of the American Society for Microbiology 1998. American Society for Microbiology, Washington, D.C. |
| 18. |
Ruiz, J.,
S. Casellas,
M. T. Jimenez de Anta, and J. Vila.
1997.
The region of the parE gene, homologous to the quinolone-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates.
J. Antimicrob. Chemother.
39:839-840 |
| 19. |
Schmitz, F.-S.,
M. E. Jones,
B. Hofmann,
B. Hansen,
S. Scheuring,
M. Lückefahr,
A. Fluit,
J. Verhoef,
U. Hadding,
H.-P. Heinz, and K. Köhrer.
1998.
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Antimicrob. Agents Chemother.
42:1249-1252 |
| 20. | Tanaka, M., Y. Onodera, Y. Uchida, K. Sato, and Y. Hayakawa. 1997. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2362-2366[Abstract]. |
| 21. |
Yoshida, H.,
M. Bogaki,
M. Nakamura,
L. M. Yamanaka, and S. Nakamura.
1991.
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
Antimicrob. Agents Chemother.
35:1647-1650 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |
